Richard Brudnick - Dec 5, 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Chief Business Officer
Signature
/s/ Karen Brown, attorney-in-fact
Stock symbol
PRME
Transactions as of
Dec 5, 2024
Transactions value $
$0
Form type
4
Date filed
12/9/2024, 06:22 PM
Previous filing
Jul 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +19.3K +50% $0.00 57.9K Dec 5, 2024 Common Stock 19.3K $7.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an option initially granted to the Reporting Person on August 4, 2022, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 19,300 shares.